Bank of America Lowers Cencora (NYSE:COR) Price Target to $360.00

Cencora (NYSE:COR) had its price objective reduced by Bank of America from $380.00 to $360.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Bank of America‘s price target would indicate a potential upside of 6.24% from the stock’s current price.

Several other analysts have also recently issued reports on COR. Wells Fargo & Company upped their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Mizuho boosted their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Robert W. Baird set a $392.00 price target on Cencora in a report on Tuesday, December 16th. Finally, TD Cowen increased their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.50.

Cencora Price Performance

COR stock opened at $338.87 on Monday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The company has a market capitalization of $65.74 billion, a PE ratio of 42.63, a price-to-earnings-growth ratio of 1.61 and a beta of 0.66. The company’s fifty day moving average price is $349.59 and its 200-day moving average price is $316.84. Cencora has a one year low of $225.75 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts anticipate that Cencora will post 15.37 EPS for the current fiscal year.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 over the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. Integrated Wealth Concepts LLC raised its holdings in Cencora by 42.5% in the first quarter. Integrated Wealth Concepts LLC now owns 8,008 shares of the company’s stock valued at $2,227,000 after acquiring an additional 2,389 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Cencora by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,588 shares of the company’s stock valued at $14,346,000 after buying an additional 5,655 shares during the last quarter. Kestra Investment Management LLC raised its position in Cencora by 45.4% in the 1st quarter. Kestra Investment Management LLC now owns 5,003 shares of the company’s stock valued at $1,391,000 after purchasing an additional 1,562 shares during the last quarter. Ashton Thomas Private Wealth LLC boosted its stake in shares of Cencora by 1.3% during the first quarter. Ashton Thomas Private Wealth LLC now owns 5,581 shares of the company’s stock worth $1,552,000 after buying an additional 73 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in Cencora during the 1st quarter worth approximately $1,450,000. 97.52% of the stock is owned by institutional investors and hedge funds.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.